Du är här

2015-09-15

Sanofi : Sanofi successfully prices EUR 2.0 billion bond issue

Sanofi successfully prices EUR 2.0 billion bond issue

Paris, France - September 15, 2015 -
Sanofi announces that it has successfully priced its offering of EUR 2.0
billion of notes across 3 tranches:

* EUR 750 million Floating Rate Notes, due 2019, bearing interest at a
quarterly rate of 3-month Euribor + 0.30%
* EUR 500 million Fixed Rate Notes, due 2021, bearing interest at an annual
rate of 0.875%
* EUR 750 million Fixed Rate Notes, due 2025, bearing interest at an annual
rate of 1.500%

The issue is drawn under the Company's Euro Medium Term Note Programme.

The transaction enables the Group to lower its average cost of debt and extend
the average maturity of its debt.

Sanofi intends to use the net proceeds of the offering for general corporate
purposes, including the repayment of existing borrowings.

Bank of America - Merrill Lynch, HSBC, Société Générale CIB, and Unicredit
were Bookrunners for the offering.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs. Sanofi has core strengths
in diabetes solutions, human vaccines, innovative drugs, consumer healthcare,
emerging markets, animal health and Genzyme. Sanofi is listed in Paris
(EURONEXT:SAN) and in New York (NYSE:SNY).

DISCLAIMER

This communication shall not constitute an offer to sell or the solicitation
of an offer to buy nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
any such state or jurisdiction.

The notes have not been and will not be registered under the Securities Act
and may not be offered or sold within the United States or to, or for the
account or benefit of, U.S. persons except in certain transactions exempt
from the registration requirements of the Securities Act.

This communication is only being distributed to and is only directed at (i)
persons who are outside the United Kingdom or (ii) investment professionals
falling within Article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005 (the "Order") or (iii) high net worth
companies, and other persons to whom it may lawfully be communicated, falling
within Article 49(2)(a) to (d) of the Order or (iv) persons to whom an
invitation or inducement to engage in investment activity (within the meaning
of section 21 of the Financial Services and Markets Act 2000) may otherwise
lawfully be communicated or cause to be communicated (all such persons
together being referred to as "relevant persons"). The notes are only
available to, and any invitation, offer or agreement to subscribe, purchase
or otherwise acquire such notes will be engaged in only with, relevant
persons. Any person who is not a relevant person should not act or rely on
this document or any of its contents.

No prospectus (including any amendment, supplement or replacement thereto) or
any other offering material has been prepared in connection with the offering
of the notes that has been approved by the Autorité des marchés financiers or
notified to the Autorité des marchés financiers after approval by the
competent authority of another member State of the European Economic Area; no
notes have been offered or sold nor will be offered or sold, directly or
indirectly, to the public in France; the prospectus or any other offering
material relating to the notes have not been distributed or caused to be
distributed and will not be distributed or caused to be distributed to the
public in France; such offers, sales and distributions have been and shall
only be made in France to persons licensed to provide the investment service
of portfolio management for the account of third parties or to qualified
investors (
investisseurs qualifiés) other than individuals, investing for their own
account, all as defined in
Articles L. 411-2, L. 411-2 and D. 411-1 of the French
Code monétaire et financier.

Forward-Looking Statements
Any statements made in this communication that are not statements of
historical fact, including statements about Sanofi's beliefs and expectations
are forward-looking statements and should be evaluated as such.
Forward-looking statements include statements that may relate to Sanofi's
plans, objectives, strategies, goals, future events, future revenues or
performance, and other information that is not historical information. Sanofi
does not undertake, and specifically disclaims, any obligation or
responsibility to update or amend any of the information above except as
otherwise required by law.

Additional Information:
This communication is neither an offer to purchase nor a solicitation of any
offer to sell any securities, nor shall there be any sale of securities in
any jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such
jurisdiction.

---------------------------------------
Contacts:

----------------------------------------------------------
| Media Relations Investor Relations |
| Laurence Bollack Sébastien Martel |
| Tel.: + (33) 1 53 77 46 46 Tel.: + (33) 1 53 77 45 45 |
| mr@sanofi.com ir@sanofi.com |
----------------------------------------------------------
Press release (PDF)
http://hugin.info/152918/R/1951976/709909.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sanofi via Globenewswire

HUG#1951976

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.